| Name | Title | Contact Details |
|---|
Symbiomix (sim-bye-OH-mix) is a late-stage, privately held biopharmaceutical company developing innovative medicines for serious women`s health infections that have been long neglected and are in need of new therapeutic options. Symbiomix was founded in 2012 by a team of experienced industry professionals and entrepreneurs and is backed by three of the world`s leading healthcare venture capital firms, OrbiMed, Fidelity Biosciences and HBM Partners. The Company`s lead product is SYM-1219, a novel drug candidate containing secnidazole, which is a next generation 5-nitroimidazole antibiotic. Symbiomix is based in New Jersey, with additional offices in Maryland and Connecticut.
Frontline Dental Implant Specialists (FDIS) is a dental implant partnership network that brings together top dental implant specialists with over 150+ years of combined experience.
The American College of Veterinary Surgeons is the specialty board that defines the standards of surgical excellence for the field of veterinary medicine, promotes advancements in veterinary surgery, and provides the latest in veterinary surgical educa...
Health One is a Ridgeland, MS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Abeona Therapeutics is focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. Abeona’s lead program is an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome (MPS IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians. Clinical trials for Sanfilippo types A and B are anticipated to begin in 2015.